AU2016372570B2 - Intravesical therapy for bladder cancer - Google Patents

Intravesical therapy for bladder cancer Download PDF

Info

Publication number
AU2016372570B2
AU2016372570B2 AU2016372570A AU2016372570A AU2016372570B2 AU 2016372570 B2 AU2016372570 B2 AU 2016372570B2 AU 2016372570 A AU2016372570 A AU 2016372570A AU 2016372570 A AU2016372570 A AU 2016372570A AU 2016372570 B2 AU2016372570 B2 AU 2016372570B2
Authority
AU
Australia
Prior art keywords
composition
antibodies
bladder
bladder cancer
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016372570A
Other languages
English (en)
Other versions
AU2016372570A1 (en
Inventor
Kjetil Hestdal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Photocure ASA
Original Assignee
Photocure ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure ASA filed Critical Photocure ASA
Publication of AU2016372570A1 publication Critical patent/AU2016372570A1/en
Application granted granted Critical
Publication of AU2016372570B2 publication Critical patent/AU2016372570B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2016372570A 2015-12-17 2016-12-19 Intravesical therapy for bladder cancer Active AU2016372570B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1522311.8A GB201522311D0 (en) 2015-12-17 2015-12-17 Use
GB1522311.8 2015-12-17
PCT/EP2016/081798 WO2017103280A1 (en) 2015-12-17 2016-12-19 Intravesical therapy for bladder cancer

Publications (2)

Publication Number Publication Date
AU2016372570A1 AU2016372570A1 (en) 2018-07-12
AU2016372570B2 true AU2016372570B2 (en) 2024-01-18

Family

ID=55311161

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016372570A Active AU2016372570B2 (en) 2015-12-17 2016-12-19 Intravesical therapy for bladder cancer

Country Status (12)

Country Link
US (2) US20180371101A1 (enExample)
EP (1) EP3390448B1 (enExample)
JP (1) JP2018538308A (enExample)
KR (1) KR102878726B1 (enExample)
CN (1) CN108699147B (enExample)
AU (1) AU2016372570B2 (enExample)
DK (1) DK3390448T3 (enExample)
ES (1) ES2981986T3 (enExample)
FI (1) FI3390448T3 (enExample)
GB (1) GB201522311D0 (enExample)
PL (1) PL3390448T3 (enExample)
WO (1) WO2017103280A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3344656A1 (en) 2015-09-01 2018-07-11 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
MX2020005692A (es) * 2017-12-01 2020-09-25 Sbi Pharmaceuticals Co Ltd Composicion farmaceutica para mejorar el efecto antitumoral mediante el inhibidor del punto de control inmunitario.
EP4676462A1 (en) 2023-03-07 2026-01-14 Photocure ASA Therapy for bladder cancer
WO2026052815A1 (en) 2024-09-05 2026-03-12 Photocure Asa Use of hal in a method for predicting bladder cancer immunotherapy response

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ303251A (en) 1995-03-10 2000-10-27 Photocure Asa Use of esters of 5-aminolevulinic acid as photosensitising agents in photochemotherapy
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
PL2342226T3 (pl) * 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2739358B1 (en) 2011-08-01 2018-11-28 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
JP6312659B2 (ja) 2012-05-31 2018-04-18 ジェネンテック， インコーポレイテッド Ｐｄ−１系結合アンタゴニスト及びｖｅｇｆアンタゴニストを用いた癌の治療方法
CN108135934B (zh) * 2015-10-19 2024-09-10 永恒生物科技股份有限公司 通过组合疗法治疗实体或淋巴肿瘤的方法
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Bader, M. et al., 'Photodynamic Therapy of Bladder Cancer—A Phase I Study Using Hexaminolevulinate (HAL)', Urologic Oncology: Seminars and Original Investigations, (2013), vol. 31, no. 7, pp. 1178-1183, doi: 10.1016/j.urolonc.2012.02.007 *
Hurwitz, M. et al., Journal of Clinical Oncology; 2015 ASCO Annual Meeting Abstracts , (2015-05-29), vol. 33, no. 15, DOI: 10.1200/jco.2015.33.15_suppl.e15504. *
Jokisch, J. et al., 'Intravesical immunotherapy in nonmuscle invasive bladder cancer', Indian Journal of Urology, (2015-10-01), vol. 31, pages 304-311, DOI: 10.4103/0970-1591.166452. *
Saylor, B., 'Product Preview: Agreement reached for phase III clinical trial of bladder Ca agent', Urology Times, (2015-09-01), XP055355483. *
Sundararajan, S. & Vogelzang, N. 'Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?', Future Oncology, (2015-08-01), vol. 11, no. 16, pages 2299 - 2306, DOI: 10.2217/fon.15.162. *

Also Published As

Publication number Publication date
GB201522311D0 (en) 2016-02-03
US20180371101A1 (en) 2018-12-27
FI3390448T3 (fi) 2024-07-10
BR112018012116A2 (en) 2018-12-04
KR20180094988A (ko) 2018-08-24
AU2016372570A1 (en) 2018-07-12
EP3390448A1 (en) 2018-10-24
WO2017103280A9 (en) 2017-11-09
US11066478B2 (en) 2021-07-20
CN108699147B (zh) 2022-11-01
WO2017103280A1 (en) 2017-06-22
CA3008548A1 (en) 2017-06-22
ES2981986T3 (es) 2024-10-14
KR102878726B1 (ko) 2025-10-29
DK3390448T3 (da) 2024-07-22
PL3390448T3 (pl) 2024-09-16
CN108699147A (zh) 2018-10-23
JP2018538308A (ja) 2018-12-27
EP3390448B1 (en) 2024-06-05
US20190241672A1 (en) 2019-08-08
RU2018124866A3 (enExample) 2020-02-26
RU2018124866A (ru) 2020-01-17

Similar Documents

Publication Publication Date Title
US11066478B2 (en) Intravesical therapy for bladder cancer
US11311620B2 (en) Neoadjuvant therapy for bladder cancer
AU2016372575B2 (en) Method of photodynamic therapy (PDT) for bladder cancer
Guo et al. Self-assembled Camptothecin derivatives–Curcuminoids conjugate for combinatorial chemo-photodynamic therapy to enhance anti-tumor efficacy
CA3008548C (en) Intravesical therapy for bladder cancer
CA3008551C (en) Neoadjuvant therapy for bladder cancer
RU2779543C2 (ru) Внутрипузырная терапия для рака мочевого пузыря
RU2783177C2 (ru) Неоадъювантная терапия для рака мочевого пузыря
WO2024184417A1 (en) Therapy for bladder cancer
BR112018012116B1 (pt) Uso de anticorpos anti-pd-l1 e/ou anticorpos anti-pd-1 e éster hexílico de 5-ala ou um sal farmaceuticamente aceitável do mesmo

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)